{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:09:29Z","timestamp":1778479769483,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The co-occurrence of hypertension and abnormal glucose metabolism\u2014a spectrum encompassing prediabetes and diabetes\u2014substantially elevates the risk of cardiovascular disease (CVD). Effective management of this high-risk clinical overlap remains a therapeutic challenge. Yiqi-Shengjin granules (YQSJ), a traditional Chinese herbal formulation, have been employed as a hospital preparation at Beijing Hospital of Traditional Chinese Medicine for over three decades, primarily for the management of glucose metabolism disorders, with an annual treatment cohort exceeding 1,000 patients. Although preliminary clinical observations suggest potential benefits of YQSJ in patients with hypertension complicated by diabetes, robust evidence from standardized clinical trials is lacking. Therefore, a well-controlled clinical study is warranted to systematically evaluate the efficacy and safety of YQSJ in this specific population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>This will be a randomized, double-blind, placebo-controlled study. After being screened and providing signed informed consent, participants will be evenly assigned to experimental or control groups in a 1:1 ratio. The experimental group will receive YQSJ 3\u2005g twice daily and losartan 50\u2005mg once daily, whereas the control group will receive YQSJ placebo 3\u2005g twice daily and losartan 50\u2005mg once daily. The treatment period will last for a total of 8 weeks (56 days), with follow-up visits scheduled every 2 weeks. The primary endpoint will be the difference in drug efficiency between the two groups. The secondary endpoints include 24\u2005h blood pressure indicators, glucose metabolism indicators, lipid metabolism indicators, vascular damage indicators, insulin resistance indicators, oxidative stress indicators, and major adverse cardiovascular events (MACE). Safety and efficacy outcomes will be assessed both before and after the 8-week medication period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study aims to provide clinical evidence on the efficacy and safety of YQSJ in the treatment of hypertension in patients with abnormal glucose metabolism. Furthermore, we will explore the potential mechanism through which YQSJ might exert hypotensive effects and adjust glucose metabolism by examining pertinent indicators of vascular and oxidative stress, as well as its influence on clinical symptoms, risk factors associated with hypertension, and the target organs affected by this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>identifier ChiCTR2200062453.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1793094","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:27Z","timestamp":1778477367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect and safety of Yiqi-Shengjin granules in hypertension management among patients with abnormal glucose metabolism: a study protocol for a randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Haoyue","family":"Shi","sequence":"first","affiliation":[{"name":"Beijing Hospital of Traditional Chinese Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqing","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juju","family":"Shang","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Traditional Chinese Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuerui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinai","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Hospital of Traditional Chinese Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"Beijing Institute of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjing","family":"Yang","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tab\u00e1k","year":"2012","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.2337\/dc25-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.7501\/j.issn.0253-2670.2023.21.023","article-title":"Effect of oral Chinese patent medicine on arterial stiffness in patients with essential hypertension: a meta-analysis","volume":"54","author":"Zhang","year":"2023","journal-title":"Chin Tradit Herb Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e007923","DOI":"10.1161\/CIRCOUTCOMES.121.007923","article-title":"Efficacy and safety of Chinese herbal medicine compared with losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial","volume":"15","author":"Lai","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"157315","DOI":"10.1016\/j.phymed.2025.157315","article-title":"Songling Xuemaikang capsule for grade 1 hypertension at low-to-moderate risk: a multicenter randomized placebo-controlled trial","volume":"148","author":"Jiang","year":"2025","journal-title":"Phytomedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chmed.2021.08.004","article-title":"Xiaoke decoction in treatment of type II diabetes: a meta-analysis","volume":"14","author":"Zhou","year":"2022","journal-title":"Chin Herb Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.16025\/j.1674-1307.1996.01.042","article-title":"Clinical observation and experimental study of Yiqi-Shengjin granules in the treatment of diabetes mellitus","volume":"15","author":"Xia","year":"1996","journal-title":"Beijing J Tradit Chin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.16025\/j.1674-1307.2024.02.007","article-title":"Analysis of blood components and mechanism of Yiqi Shengjin powder in treating type 2 diabetes mellitus complicated with hypertension","volume":"43","author":"Shi","year":"2024","journal-title":"Beijing J Tradit Chin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.16025\/j.1674-1307.2017.12.003","article-title":"Experimental study on the effect of Yiqi Shengjin tea on insulin resistance in KKAy mice","volume":"36","author":"Xia","year":"2017","journal-title":"Beijing J Tradit Chin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jgr.2024.10.002","article-title":"Ginsenoside Rg1 improves hypoxia-induced pulmonary vascular endothelial dysfunction through TXNIP\/NLRP3 pathway-modulated mitophagy","volume":"49","author":"Zhang","year":"2025","journal-title":"J Ginseng Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/HJH.0000000000004085","article-title":"Betaine protects cerebral microvascular endothelium and ameliorates hypertension-induced cognitive dysfunction via upregulation of the endothelial nitric oxide synthase\/nitric monoxide signaling pathway","volume":"43","author":"Sun","year":"2025","journal-title":"J Hypertens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10741-025-10530-1","article-title":"Urea, TMAO, betaine and other osmolytes as endogenous diuretics in heart failure and hypertension","volume":"30","author":"Mogilnicka","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.16025\/j.1674-1307.2020.07.025","article-title":"Efficacy of Yiqi-Shengjin bag tea in pre diabetes of Qi and Yin deficiency type patients","volume":"39","author":"Tong","year":"2020","journal-title":"Beijing J Tradit Chin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.19879\/j.cnki.1005-5304.202412511","article-title":"Efficacy of Yiqi-Shengjin granules combined with conventional western medicine on diabetic heart disease and its effects on cardiac autonomic nervous function, cardiac function and inflammatory factors","volume":"32","author":"Zhai","year":"2025","journal-title":"Chin J Inf TCM"},{"key":"B20","unstructured":"Zhou\n              YJ\n            \n          \n          10.26973\/d.cnki.gbjzu.2021.000229\n          Beijing\n          Beijing University of Chinese Medicine\n          Effect of Yiqi-Shengjin granules on heart rate variability of type 2 diabetes mellitus complicated with stable angina pectoris\n          \n          2021"},{"key":"B21","volume-title":"Guidance Principle of Clinical Study on new Drug of Traditional Chinese Medicine","author":"Zheng","year":"2002"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0251654","DOI":"10.1371\/journal.pone.0251654","article-title":"Effects of combined training performed two or four times per week on 24-h blood pressure, glycosylated hemoglobin and other health-related outcomes in aging individuals with hypertension: rationale and study protocol of a randomized clinical trial","volume":"16","author":"Ferrari","year":"2021","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cca.2014.08.042","article-title":"The \u201ccardiometabolic index\u201d as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus","volume":"438","author":"Wakabayashi","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2024.02.053","article-title":"Personalized intervention based on early detection of atherosclerosis","volume":"83","author":"Nielsen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11883-021-00913-8","article-title":"Preventing diabetes and atherosclerosis in the cardiometabolic syndrome","volume":"23","author":"Ahmad","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1793094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:34Z","timestamp":1778477374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1793094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2026.1793094"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1793094","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1793094"}}